0000950170-24-075071.txt : 20240618 0000950170-24-075071.hdr.sgml : 20240618 20240618175848 ACCESSION NUMBER: 0000950170-24-075071 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240614 FILED AS OF DATE: 20240618 DATE AS OF CHANGE: 20240618 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cohen Yuval CENTRAL INDEX KEY: 0001626003 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37348 FILM NUMBER: 241053374 MAIL ADDRESS: STREET 1: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC STREET 2: 100 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Corbus Pharmaceuticals Holdings, Inc. CENTRAL INDEX KEY: 0001595097 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464348039 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 BUSINESS PHONE: 617-963-0103 MAIL ADDRESS: STREET 1: 500 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 FORMER COMPANY: FORMER CONFORMED NAME: SAV Acquisition Corp DATE OF NAME CHANGE: 20131220 4 1 ownership.xml 4 X0508 4 2024-06-14 0001595097 Corbus Pharmaceuticals Holdings, Inc. CRBP 0001626003 Cohen Yuval C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE NORWOOD MA 02062 true true false false Chief Executive Officer true Common Stock, par value $0.0001 per share 2024-06-14 4 M false 16830 14.10 A 101230 D Common Stock, par value $0.0001 per share 2024-06-14 4 S false 16830 50.1662 D 84400 D Common Stock, par value $0.0001 per share 2024-06-14 4 M false 12487 4.26 A 96887 D Common Stock, par value $0.0001 per share 2024-06-14 4 S false 12487 50.1662 D 84400 D Common Stock, par value $0.0001 per share 2024-06-17 4 M false 9333 30 A 93733 D Common Stock, par value $0.0001 per share 2024-06-17 4 S false 9333 46.0203 D 84400 D Common Stock, par value $0.0001 per share 2024-06-17 4 M false 1770 4.26 A 86170 D Common Stock, par value $0.0001 per share 2024-06-17 4 S false 1770 46.0203 D 84400 D Common Stock, par value $0.0001 per share 2024-06-18 4 M false 11667 30 A 96067 D Common Stock, par value $0.0001 per share 2024-06-18 4 S false 11667 42.237 D 84400 D Common Stock, par value $0.0001 per share 2024-06-18 4 M false 1770 14.10 A 86170 D Common Stock, par value $0.0001 per share 2024-06-18 4 S false 1770 42.237 D 84400 D Common Stock, par value $0.0001 per share 2024-06-18 4 M false 2322 4.26 A 86722 D Common Stock, par value $0.0001 per share 2024-06-18 4 S false 2322 42.237 D 84400 D Common Stock, par value $0.0001 per share 2024-06-18 4 S false 7179 42.237 D 77221 D Options to purchase common stock 14.1 2024-06-14 4 M false 16830 0 D 2023-02-01 2032-02-01 Common Stock 16830 32827 D Options to purchase common stock 4.26 2024-06-14 4 M false 12487 0 D 2024-02-13 2033-02-13 Common Stock 12487 53831 D Options to purchase common stock 30 2024-06-17 4 M false 9333 0 D 2024-10-22 Common Stock 9333 11667 D Options to purchase common stock 4.26 2024-06-17 4 M false 1770 0 D 2024-02-13 2033-02-13 Common Stock 1770 52061 D Options to purchase common stock 30 2024-06-18 4 M false 11667 0 D 2024-10-22 Common Stock 11667 0 D Options to purchase common stock 14.10 2024-06-18 4 M false 1770 0 D 2023-02-01 2032-02-01 Common Stock 1770 31057 D Options to purchase common stock 4.26 2024-06-18 4 M false 2322 0 D 2024-02-13 2033-02-13 Common Stock 2322 49739 D This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.27 to $52.23 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0 to $49.38 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.75 to $43.69 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. /s/Yuval Cohen 2024-06-18